Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25703657 | 0.82 | FLT3 (0.46) | ADORA3NPC1RAB9ANPSR1FLT3 | |
| SCHEMBL9525882 | 0.82 | TGFBR1 (0.46) | ADORA3NPC1RAB9ANPSR1FLT3 | |
| SCHEMBL3155189 | 0.82 | ADORA3 (0.44) | ADORA3NPC1RAB9ANPSR1FLT3 | |
| SCHEMBL24803763 | 0.79 | ADORA3 (0.42) | ADORA3NPC1RAB9ANPSR1FLT3 | |
| SCHEMBL30977360 | 0.76 | KDR (0.40) | NPC1RAB9AFLT3PKMALDH1A1 | |
| SCHEMBL17697692 | 0.74 | POLB (0.46) | NPC1RAB9AFLT3 | |
| SCHEMBL9075915 | 0.73 | EPHB3 (0.41) | ADORA3NPC1RAB9ANPSR1EPHB3 | |
| SCHEMBL21808337 | 0.73 | HTR2A (0.42) | ADORA3NPC1RAB9ANPSR1FLT3 | |
| SCHEMBL17697688 | 0.72 | MAP3K14 (0.41) | FLT3HTR6PIK3CAMTORDYRK1A | |
| SCHEMBL4557281 | 0.71 | AKR1B1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024017857-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023150526-A1 | COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| WO-2013001505-A2 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2013-01-03 | — | — | WO | disclosed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | ADORA3 2516/4885NPC1 16/4885RAB9A 2242/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | ADORA3 77/4885NPC1 2563/4885RAB9A 1907/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | ADORA3 1359/4885NPC1 3262/4885RAB9A 417/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | ADORA3 2431/4885NPC1 515/4885RAB9A 1359/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | ADORA3 2982/4885NPC1 3215/4885RAB9A 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.